Rigenera protocol in the treatment of surgical wound dehiscence

Abstract

The effective management of post-operative wounds is important to prevent potential complications such as surgical-site infections and wound dehiscence. The purpose of this study was to treat wound dehiscence in elderly patients who were subjected to orthopaedic surgical interventions. The dehisced wounds were treated with autologous micro-grafts obtained using a promising CE-certified medical device called Rigeneracons. This instrument is a biological disruptor of human tissues able to specifically select progenitor cells that, as already reported in previous studies, maintain high cell viability but mainly have a high regenerative potential, allowing the repair of damaged tissues. Autologous micro-grafts obtained by Rigeneracons are ready to use and can be applied alone or in combination with biological scaffolds directly on the injured area. We observed in our patients a complete remission of dehisced wounds, on average, after 30 days from micro-grafts application and a total wound re-epithelialisation after 1 year from the surgical intervention. In conclusion, although we reported only three patients, autologous micro-grafts can be considered a promising approach for the treatment of dehisced wounds, improving the wound-healing process and in general the patient's quality of life without using other dressings.

In Vitro and In Vivo Studies of Alar-Nasal Cartilage Using Autologous Micro-Grafts: The Use of the Rigenera® Protocol in the Treatment of an Osteochondral Lesion of the Nose

“…The rationale behind the Rigenera ® protocol lies in the multipotent properties of mesenchymal stem cells, which may promote cell differentiation and subsequent new cartilage formation [23,24,25]. The Rigenera ® protocol opens new surgical strategies especially for tissue repair.…”

“…Compared to enzymatic techniques, mechanical disaggregation has claimed to be faster and safer. So far, the Rigenera ® protocol has shown clinical efficacy in the management of complex wounds [24,25] and for the regeneration of the bone in periodontal surgeries [26]. In this preliminary study, we initially analyzed micro-grafts obtained from human and murine auricular cartilage tissues with in vitro tests in order to characterize the population of cells obtained by the mechanical disaggregation.…”

Exploring Wound-Healing Genomic Machinery with a Network-Based Approach

“…)-certified medical portable device. Rigenera ® produces autologous micro-grafts enriched with progenitor cells, which maintain high cell viability due to its high regenerative potential, allowing the repair of damaged tissues [7]. Moreover, in the Rigenera ® protocol, the donor and acceptor are the same individual, preventing possible complications with respect to conventional implants of no autologous micro-grafts [8].…”

“…Moreover, in the Rigenera ® protocol, the donor and acceptor are the same individual, preventing possible complications with respect to conventional implants of no autologous micro-grafts [8]. Despite its widespread use in clinical practice [7,8,9,10,11] and its efficacy in boosting tissue regeneration, the genetic and molecular processes regulated by Rigenera ® are still unclear. In particular, the mechanism of Rigenera ® related to gene expression is still unknown, and further in vitro analysis is required.…”

“…In particular, the mechanism of Rigenera ® related to gene expression is still unknown, and further in vitro analysis is required. Current clinical studies based on the Rigenera ® protocol attribute the effects of Rigenera ® to the presence of mesenchymal stem cells, already analyzed by fluorescence-activated cell sorting (FACS) analyses [7,8,9,11]. …”